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A B S T R A C T
Background: The high variability in clinical outcome of patients with Classical Galactosemia (CG) is poorly
understood and underlines the importance of prognostic biomarkers, which are currently lacking. The aim of this
study was to investigate if residual galactose metabolism capacity is associated with clinical and biochemical
outcomes in CG patients with varying geno- and phenotypes.
Methods: Galactose Metabolite Profiling (GMP) was used to determine residual galactose metabolism in fibro-
blasts of CG patients. The association between the galactose index (GI) defined as the ratio of the measured
metabolites [U13C]Gal-1-P/ [13C6]UDP-galactose, and both intellectual and neurological outcome and galactose-
1-phosphate (Gal-1-P) levels was investigated.
Results: GMP was performed in fibroblasts of 28 patients and 3 control subjects. The GI of the classical phe-
notype patients (n=22) was significantly higher than the GI of four variant patients detected by newborn
screening (NBS) (p= .002), two homozygous p.Ser135Leu patients (p= .022) and three controls (p= .006). In
the classical phenotype patients, 13/18 (72%) had a poor intellectual outcome (IQ < 85) and 6/12 (50%) had a
movement disorder. All the NBS detected variant patients (n=4) had a normal intellectual outcome (IQ≥85)
and none of them has a movement disorder. In the classical phenotype patients, there was no significant dif-
ference in GI between patients with a poor and normal clinical outcome. The NBS detected variant patients had
significantly lower GI levels and thus higher residual galactose metabolism than patients with classical phe-
notypes. There was a clear correlation between Gal-1-P levels in erythrocytes and the GI (p= .001).
Conclusions: The GI was able to distinguish CG patients with varying geno- and phenotypes and correlated with
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Gal-1-P. The data of the NBS detected variant patients demonstrated that a higher residual galactose metabolism
may result in a more favourable clinical outcome. Further research is needed to enable individual prog-
nostication and treatment in all CG patients.
1. Introduction
Classical Galactosemia (CG) is an autosomal recessive inborn error
of galactose metabolism. Due to a deficiency of the galactose-1-phos-
phate uridylyltransferase enzyme (EC 2.7.7.12; GALT) patients are
unable to metabolize galactose, which leads to the accumulation of
galactose-1-phosphate (Gal-1-P) and galactitol. The only available
treatment is a galactose restricted diet. An early onset of the diet (after
newborn screening (NBS) or family screening) improves neonatal out-
come, but an early onset of and good compliance with the diet do not
prevent long-term complications such as cognitive impairment, move-
ment disorders and in females primary ovarian insufficiency [1–5]. The
pathophysiology of CG and the broad clinical outcome spectrum ran-
ging from fully normal to severely impaired are poorly understood. In
patients with a GALT deficiency, Gal-1-P is persistently elevated even in
dietary adherent patients, due to the endogenous production of ga-
lactose [6,7]. Both the accumulation of Gal-1-P and the reduced pro-
duction of important substrates such as UDP sugars, are thought to
contribute to the glycosylation defects demonstrated in CG patients and
may thus contribute to the long-term complications [8–12]. At this
time, there are no biomarkers that can predict the clinical outcome of
CG patients. Prognostic biomarkers are urgently needed in all patients,
but especially in patients with a classical phenotype in which clinical
outcome varies highly and in patients detected since the implementa-
tion of NBS with previously unreported clinical and biochemical gen-
otypes and phenotypes [13].
We hypothesize that differences in clinical outcome are caused by
differences in residual galactose metabolism capacity. A slightly higher
ability to metabolize galactose would cause lower Gal-1-P levels
resulting in less abnormal galactosylation and possibly a more favour-
able clinical outcome. The method that is currently used in our cohort
to measure erythrocyte GALT enzyme activity is not able to reliably
detect differences in enzyme activity below 3.3% (<1.1 umol/h.g Hb).
To study the correlation between residual enzyme activity and clinical
outcome, other methods should be investigated that are able to reliably
detect (even slight) differences in residual galactose metabolism capa-
city. Metabolite profiling in fibroblasts has been demonstrated to cor-
relate well with clinical severity in other metabolic disorders such as
inborn errors of fatty acid oxidation [14,15]. In our pilot study we
found that galactose metabolite profiling (GMP) in cultured fibroblasts
was a sensitive method to determine residual galactose metabolism
capacity expressed as the Galactose Index (GI). This method was able to
differentiate between patients with a classical phenotype, patients with
a variant phenotype and controls [16].
The aim of this study was to determine if residual galactose meta-
bolism measured in fibroblasts can be used as predictor of clinical
outcome by investigating the association between the GI and both
biochemical and clinical outcomes in CG patients with varying geno-
types and phenotypes.
2. Materials and methods
2.1. Patients and controls
Galactose metabolite profiling (GMP) was performed in fibroblasts
of GALT deficient patients with two known pathogenic variations in the
GALT gene and/or an erythrocyte GALT enzyme activity< 15% of the
reference mean and were collected for clinical or research purposes.
Table 1
Patient demographics and clinical outcomes.
Pt ID Pt ID⁎ Group GALT_1 / GALT_2 GALT activity, % GI IQ MD
1 12 C p.Gln188Arg / p.Gln188Arg < 3.3 14.27 81 Yes
2 14 C p.Gln188Arg / p.Gln188Arg < 3.3 18.53 78 –
3a 13 C p.Gln188Arg / p.Gln188Arg < 3.3 16.65 77 Yes
4a 8 C p.Gln188Arg / p.Gln188Arg < 3.3 15.58 71 –
5 10 C p.Gln188Arg / p.Gln188Arg < 3.3 22.37 83 –
6 4 C p.Gln188Arg / p.Gln188Arg – 13.94 91 –
7 9 C p.Gln188Arg / p.Gln188Arg – 11.49 53 No
8 7 C p.Gln188Arg / p.Gln188Arg < 3.3 17.49 82 No
9 – C p.Gln188Arg / p.Gln188Arg < 3.3 14.00 – –
10 – C p.Gln188Arg / p.Gln188Arg < 3.3 13.16 – –
11 – C p.Gln188Arg / p.Gln188Arg < 3.3 10.12 – No
12 – C p.Gln188Arg / p.Gln188Arg < 3.3 10.77 – No
13 31 C p.Gln188Arg / p.Lys127E < 3.3 18.98 70 –
14 21 C p.Gln188Arg / p.Ser135Trp < 3.3 13.49 98 No
15 27 C p.Gln188Arg / p.Lys285Asn < 3.3 16.18 77 –
16 34 C p.Ser135Trp / p.Arg51Gln < 3.3 12.87 78 –
17b 17 C p.Gln188Arg / p.Leu195Pro < 3.3 9.04 52 Yes
18b 19 C p.Gln188Arg / p.Leu195Pro < 3.3 11.08 88 Yes
19 30 C p.Gln188Arg / p.Lys127E < 3.3 13.76 61 –
20 18 C p.Gln188Arg / p.Leu195Pro < 3.3 16.71 93 No
21c 26 C p.Gln188Arg / p.Lys285Asn < 3.3 13.73 86 Yes
22c 25 C p.Gln188Arg / p.Lys285Asn < 3.3 16.54 76 Yes
23 36 S p.Ser135Leu / p.Ser135Leu 3.9 5.40 61 No
24 37 S p.Ser135Leu / p.Ser135Leu < 3.3 2.47 71 No
25 38 V p.Gln188Arg / p.Met219Lys 7.2 4.52 96 No
26 39 V p.Gln188Arg / c.1-96 T > G 3.6 6.31 86 No
27 – V p.Val128Ile / p.Val128Ile 9.3 7.17 91 No
28 – V p.Arg201His / p.Arg201His 8.9 1.61 – –
⁎ Patient (Pt) ID whole body galactose oxidation study. C: Classical phenotype, S: homozygous p.Ser135Leu, V: Variant patients, IQ: Intelligence Quotient, MD:
Movement Disorder. a,b,c: sibs. -: missing data.
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The fibroblasts collected for clinical reasons were used after patients or
their parents gave informed consent. The research fibroblasts were
collected from competent, adult patients after informed consent was
obtained. All patients consented to the use of their clinical data for
research purposes. This study was approved by the local medical ethics
committee. The fibroblasts of healthy controls were collected for re-
search purposes after informed consent and approval of the local
medical ethics committee.
2.2. Patient groups
This cohort comprises GALT deficient patients with varying geno-
and phenotypes; patients with classical phenotypes (two pathogenic
GALT mutations and absent or barely detectable erythrocyte GALT
activity), NBS detected variant patients (since 2007, with previously
unreported geno- and phenotypes and erythrocyte GALT activity up to
10%, no clinical symptoms at diagnosis and undetectable Gal-1-P levels
on dietary treatment) [13] and patients with the homozygous
p.Ser135Leu genotype with residual GALT activity in other tissues than
erythrocytes [17]. Patient demographics are listed in Table 1.
2.3. GMP measurements
The cell culture procedure and stable isotope 13C labeled GMP
measurements in fibroblasts were carried out as previously described
[16]. In brief, fibroblasts were starved for 16 h in Dulbecco's phosphate
buffered saline, followed by addition of 1mM of [U13C]Galactose. After
an incubation period of 4 h metabolism was quenched and cells were
processed for measurement of [U13C]Galactose, [U13C]Gal-1-P and
[13C6]UDP-galactose. The galactose index (GI) was defined as the ratio
of [U13C]Gal-1-P/ [13C6]UDP-galactose. The GMP measurements were
performed in triplicate and each patient cell line was measured in two
independent experiments. Every experiment included at least two cell
lines from control subjects and at least one cell line of a patient with a
classical phenotype. The result (the GI) is the mean of the two in-
dependent experiments.
2.4. Clinical outcome
The clinical outcome parameters were intellectual and neurological
outcome. In patients who received an age specific intelligence test, the
IQ was used as derivative of intelligence. A poor intellectual outcome
was defined as an IQ < 85 and a normal intellectual outcome as an
IQ≥85. The presence or absence of movement disorders (MDs) was
used as a determinant for neurological outcome. Information was re-
trieved from the medical records of the included patients.
2.5. Biochemical outcome
The most recent Gal-1-P level documented in the medical charts of
patients was used in this study. All included Gal-1-P levels were mea-
sured by gas chromatography mass spectrometry (GC–MS) in ery-
throcytes and were below 0.82 μmol/g Hb in diet adherent patients.
Patients with self-reported dietary incompliance at the most recent Gal-
Table 2
Galactose Index (GI).
N Galactose Index
All patients 28 13.61 (1.61–22.37)
Classical phenotypes 22 13.97 (9.04–22.37)
NBS variant patients 4 5.42 (1.61–7.17)
Homozygous p.Ser135Leu 2 3.94 (2.47–5.40)
Controls 3 1.03 (0.84–1.12)
Notes. Data reported in median (ranges), NBS: newborn screening.
Fig. 1. Individual data on the Galactose Index (GI) and IQ (1A), GI and whole body galactose oxidation capacity after 120min (CUMPCDT120) (1B) and GI and
galactose-1-phophate (Gal-1-P) (1C) in Classical Galactosemia patients with varying phenotypes and controls.
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1-P measurement were excluded from the Gal-1-P analysis.
2.6. Statistical analyses
SPSS version 25 (SPSS Inc. Chicago, Illinois, USA) was used to
perform all statistical analyses. Data were presented as median and
ranges because of a non-normal distribution. The Mann-Whitney U test
was used to determine if statistically significant differences in GI were
present between patients with a poor and normal clinical outcome. The
Spearman's rank coefficient test was used to test for associations and
regression analysis was used to test for correlations. P-values below
0.05 were considered statistically significant.
3. Results
3.1. Patients
Fibroblast samples of 28 patients were included in this study. Of the
included patients, 22 were classified as patients with a classical phe-
notype (12 patients with the homozygous p.Gln188Arg genotype) and
four as NBS variant phenotype. Two patients were homozygous for the
p.Ser135Leu mutation. Residual GALT enzyme activity in erythrocytes
was below the limit of quantitation of the enzyme assay
(< 3.3%;< 1.1 μmol/h.g Hb) in 21/26 (Table 1). In two patients, the
erythrocyte GALT enzyme activity was not documented.
3.2. GMP measurements
Galactose metabolite profiling (GMP) was performed in fibroblasts
of 28 GALT deficient patients and three control subjects and the GI was
calculated (Table 1, Table 2 and Fig. 1). The GI of the classical phe-
notype patients was significantly higher than of the NBS detected var-
iants (p= .002), the homozygous p.Ser135Leu patients (p= .022) and
controls (p= .006). The GI of the NBS detected variants was also sig-
nificantly higher than of the controls (p= .034). The GI of the homo-
zygous p.Ser135Leu patients was increased compared to the controls
but the difference was not significant, probably due to the limited
numbers (p= .083). The GI was significantly lower in pediatric patients
when compared to adult patients (p= .030). In the classical phenotype
group, there was no significant difference in GI between pediatric and
adult patients. There was no significant difference in GI between males
and females.
The results of the individual GMP measurements including the
coefficient of variation (CV) are listed in the supplementary Table 1.
One experiment contained several outliers and therefore the entire
experiment (the GMP measurements of 7 classical phenotype patients, 2
variants and 2 controls in triplicate) was excluded.
3.3. The association between GI and clinical outcome
Our cohort included four NBS detected variant patients with pre-
viously unreported genotypes and higher residual GALT enzyme ac-
tivity than the patients with classical phenotypes, and two homozygous
p.Ser135Leu patients who were diagnosed at a later age (7months and
10 years respectively) with residual GALT enzyme activity in other
tissues. Since both the genotype and the late initiation of dietary
treatment may influence clinical outcome, analyses were carried out
both with and without these patients.
3.4. Intellectual outcome
The intellectual outcome of 24 patients was known, with an IQ
ranging from 52 to 98 (median 78). The intellectual outcome was poor
in 15/24 (IQ < 85) and normal in 9/24 (IQ≥ 85). Overall, the GI in
patients with a poor intellectual outcome was higher when compared to
patients with a normal intellectual outcome, but the difference was not
significant (p= .053) (Table 3). After the homozygous p.Ser135Leu
patients were excluded, the GI became significantly higher GI in pa-
tients with a poor intellectual outcome (p= .010). In the group of
classical phenotype patients, there was no significant difference in GI
between patients with a poor and normal intellectual outcome. Overall,
there was no correlation between the IQ (as continuous variable) and GI
(Fig. 1A).
3.5. Neurological outcome
In our cohort, a movement disorder (MD; tremor and/or dystonia)
was reported in 6/17 patients. Overall, the GI in patients with an MD
was higher when compared to patients without an MD, but the differ-
ence was not significant (p= .132) (Table 3). The exclusion of the
homozygous p.Ser135Leu patients did not change this finding. In the
group of classical phenotype patients, there was no significant differ-
ence in GI between patients with and without an MD.
3.6. The association between GI and whole body galactose oxidation
This cohort includes 22 patients who have participated in a previous
study, which investigated whole body galactose oxidation with the use
of the 1-13C galactose breath test [18].
Linear regression indicated a negative correlation between the GI
and whole body galactose oxidation (F(1,20) 30.47, β-0.89 (95%CI
-1.22– −0,55), p < .0005) (Fig. 1B). In the classical phenotype pa-
tients, there was no significant correlation between the GI and whole
body galactose oxidation.
3.7. The association between the GI and biochemical outcome
For 21/28 patients, the most recent Gal-1-P value measured by
GC–MS was retrieved from the medical charts. Three NBS detected
variant patients demonstrated undetectable Gal-1-P levels
(< 0.05 μmol/g Hb) under dietary treatment. Linear regression in-
dicated a positive correlation between the GI and Gal-1-P (F(1,19)
13.89, β 2.19 (95%CI 0.96–3.43), p= .001) (Fig. 1C). In the group of
classical phenotype patients, there was no significant correlation be-
tween Gal-1-P level and GI.
Table 3
Galactose index and clinical outcome.
All patients Classical phenotypes NBS Variant patients Homozygous p.Ser135Leu
GI N
28
13.49 (1.61–22.37) N
22
13.97 (9.04–22.37) N
4
5.42 (1.61–7.17) N
2
\3.94 (2.47–5.40)
- IQ≥85: 9 11.08 (1.61–16.71) 5 13.73 (11.08–16.71) 4 5.42 (1.61–7.17) -
- IQ < 85: 15 15.58 (2.47–22.37) 13 16.18 (9.04–22.37) - 2 3.94 (2.47–5.40)
- MDs, No: 11 10.12 (2.47–17.49) 6 12.49 (10.12–17.49) 4 5.42 (1.61–7.17) 2 3.94 (2.47–5.40)
- MDs, Yes: 6 14.00 (9.04–16.65) 6 14.00 (9.04–16.65) - -
Notes. Data reported in median (ranges), GI: Galactose Index, IQ: Intelligence Quotient, MD: Movement Disorder.
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4. Discussion
In this study, we investigated the association between the GI mea-
sured in fibroblasts and the biochemical and clinical outcomes of GALT
deficient patients. The previously developed GMP assay was used to
determine residual galactose metabolism expressed as GI in a relatively
large cohort of GALT deficient patients with varying geno- and phe-
notypes.
The results of this study demonstrate that the GI is able to differ-
entiate between patients with a classical phenotype, NBS detected
variant patients with possibly better outcomes and controls, and results
are in line with the conducted pilot study [16]. Furthermore, GMP
analysis is able to distinguish homozygous p.Ser135Leu patients from
classical phenotype patients and controls.
An important issue in CG is the lack of predictors of clinical out-
come, especially in patients with a classical phenotype who have highly
variable outcomes. In our cohort of classical phenotype patients, the
differences in GI between patients with a poor and normal clinical
outcome were not significant and thus the GI was not able to predict
clinical outcome. As the GI demonstrated considerable interpatient and
inter-assay variation within the classical phenotype patients with se-
verely deficient GALT enzyme activity, the question remains whether
future studies in a larger cohort would be able to demonstrate sig-
nificant differences in GI between classical patients with a poor and
normal clinical outcome.
The variant patients detected by NBS have residual GALT enzyme
activities up to 10% in erythrocytes, significantly lower Gal-1-P levels
than classical patients and currently none of them demonstrates long-
term complications. The GI of these patients is significantly lower when
compared to classical patients and their residual galactose metabolism
capacity may prevent them from developing long-term complications,
but as they are still young (below nine years of age) a careful long-term
follow up is warranted.
The inclusion of the variant patients in our cohort resulted in a
number of correlations. Firstly, we found a significant correlation be-
tween age and GI, which was not found in our cohort of classical
phenotype patients. Secondly, we found a clear correlation between GI
and Gal-1-P levels, which is mainly due to the inclusion of the variant
patients with higher residual galactose metabolism in fibroblasts and
significantly lower Gal-1-P levels when compared to classical pheno-
type patients. Thirdly, the GI was negatively correlated with whole
body galactose oxidation capacity, which can be attributed to the in-
clusion of variant patients who demonstrated lower GI levels and higher
levels of whole body galactose oxidation than classical phenotype pa-
tients. Interestingly, within the group of classical phenotype patients
with highly variable clinical outcomes, we found no correlation be-
tween GI and both Gal-1-P levels and whole body galactose oxidation.
In the classical phenotype patients, whole body galactose oxidation was
consistently in the low range whereas the GI levels varied considerably.
The differences between residual galactose metabolism in fibroblasts
and whole body galactose oxidation might be attributed to organ spe-
cific GALT activity, which has been observed in an animal model [19].
The same study also demonstrated an age-dependent effect in different
tissues. The results of the whole body galactose oxidation study indeed
demonstrated significantly higher galactose oxidation capacity in
younger patients, also within the group of classical phenotype patients.
In the current study, GI levels were not affected by age within the group
of classical phenotype patients. Therefore both age and organ specific
GALT activity may explain the differences between whole body ga-
lactose oxidation results and GI levels.
The finding that the variant patients demonstrated higher residual
galactose metabolism in fibroblasts, lower Gal-1-P levels and possibly
better clinical outcomes supports our hypothesis that differences in
clinical outcomes are caused by differences in residual galactose me-
tabolism capacity. The fact that we did not find this correlation in
classical phenotype patients may be due to our small cohort or may
suggest that the differences in clinical outcome in this subgroup may be
attributed to other factors than residual galactose metabolism such as
modifying genes.
There may be a threshold value for residual galactose metabolism in
fibroblasts above which clinical outcome improves, but this could not
be determined based on the results of this study.
A remarkable result are the low GI levels in our homozygous
p.Ser135Leu patients with a poor intellectual outcome. Both patients
also demonstrated whole body galactose oxidation in the control range
and lower Gal-1-P levels than classical phenotype patients. Therefore,
the question remains whether their poor intellectual outcome might be
the result of the late initiation of dietary treatment as a comparable
intellectual outcome has been reported in another late diagnosed
homozygous p.Ser135Leu patient [12,20].
All variant patients were identified and treated early and none of
them demonstrates long-term complications at this moment. Possibly
their GI level provides sufficient galactose metabolism to protect
against long-term complications. Based on the results of this study, the
whole body galactose oxidation capacity and the undetectable Gal-1-P
levels in NBS detected variants, some variant patients might even
benefit from a less strict diet. Before dietary changes are implemented,
the clinical outcomes of the variant patients need further follow-up and
future studies into dietary relaxation are warranted.
4.1. Limitations
After the exclusion of outliers, the GMP measurements demon-
strated an acceptable intra-assay variation, but the inter-assay variation
was considerable especially in the group of classical phenotype pa-
tients. Despite additional analyses, a clear explanation for the variation
could not be determined. The fluctuation in GMP measurements be-
tween experiments may indicate that differences in culture and/or in-
cubation conditions influence the GMP measurements.
As previously described, the current method for GMP measurements
is limited as it is not able to differentiate [13C6]-UDP-galactose from
[13C6]-UDP-glucose and [U13C]-Gal-1-phosphate from [U13C]-glucose-
1-phosphate [16]. Considering only labeled substrates are measured
which have to pass the GALT enzyme first, this is only a small limita-
tion. The question remains whether the observed differences in GI
within the group of classical phenotype patients might be attributed to
alternative disposal pathways.
5. Conclusion
The GI measured by GMP in GALT deficient fibroblasts dis-
tinguished patients with classical phenotypes from NBS detected var-
iants and homozygous p.Ser135Leu patients. In the classical phenotype
patients, the GI was not able to differentiate between patients with a
poor and normal clinical outcome. The data of the NBS detected var-
iants support our hypothesis that a higher residual galactose metabo-
lism may result in a more favourable clinical outcome. Further research
is needed to enable individual prognostication and treatment in all CG
patients.
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